Teacher Retirement System of Texas Raises Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Teacher Retirement System of Texas boosted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 25.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 18,760 shares of the biotechnology company's stock after buying an additional 3,840 shares during the period. Teacher Retirement System of Texas' holdings in Blueprint Medicines were worth $1,636,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Blueprint Medicines in the 3rd quarter valued at $475,000. Advisors Asset Management Inc. increased its position in Blueprint Medicines by 17.6% during the third quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company's stock worth $467,000 after acquiring an additional 756 shares during the period. Charles Schwab Investment Management Inc. increased its position in Blueprint Medicines by 9.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company's stock worth $55,244,000 after acquiring an additional 50,736 shares during the period. Citigroup Inc. raised its stake in Blueprint Medicines by 19.3% in the 3rd quarter. Citigroup Inc. now owns 143,441 shares of the biotechnology company's stock worth $13,268,000 after purchasing an additional 23,189 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $108,000.

Blueprint Medicines Trading Down 3.1 %

Shares of NASDAQ BPMC traded down $2.77 during trading on Monday, reaching $85.95. The company had a trading volume of 78,681 shares, compared to its average volume of 726,698. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market cap of $5.49 billion, a P/E ratio of -79.58 and a beta of 0.58. The company's fifty day moving average price is $98.13 and its 200-day moving average price is $94.04.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BPMC. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an "outperform" rating for the company. Morgan Stanley started coverage on Blueprint Medicines in a research note on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price target for the company. Scotiabank assumed coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They set a "sector outperform" rating and a $150.00 price objective for the company. Stephens reissued an "overweight" rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, StockNews.com downgraded shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $124.95.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Ariel Hurley sold 2,250 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now owns 14,967 shares of the company's stock, valued at $1,496,700. This trade represents a 13.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,608 shares of company stock valued at $3,319,587. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.